Categories AlphaGraphs, Earnings, Leisure & Entertainment

DIS Earnings: Walt Disney Company Q3 2023 revenue rises 4%

The Walt Disney Company (NYSE: DIS) announced third-quarter 2023 results on Wednesday, reporting an increase in revenues.

The Walt Disney Company Q3 2023 earnings infographic

The Burbank-headquartered entertainment behemoth said its adjusted profit decreased to $1.03 per share in the June quarter from $1.09 per share a year earlier. On a reported basis, it was a net loss from continuing operations of $460 million or $0.25 per share, compared to a profit of $1.41 billion or $0.77 per share in the prior-year period.

Revenues increased 4% annually to $22.3 billion in the third quarter. Revenues of Disney Parks, Experiences, and Products increased by 13%.

“Our results this quarter are reflective of what we’ve accomplished through the unprecedented transformation we’re undertaking at Disney to restructure the company, improve efficiencies, and restore creativity to the center of our business,” said Robert Iger, CEO of Walt Disney.

Prior Performance

  • The Walt Disney Company Q1 2023 earnings infographic
  • Walt Disney Q4 2022 earnings infographic
  • The Walt Disney Company Q3 2022 earnings infographic

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top